metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
hepatocell cancer (HCC) hepatocell cancer (HCC)
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1	-	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-
mHCC - (neo)adjuvant (NA) metastatic/advanced hepatocellular cancer (mHCC) mHCC - (neo)adjuvant (NA)
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1	-	-	-
mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)
versus sorafenib
	durvalumab plus tremelimumab vs. sorafenib	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-
mHCC - 2nd line (L2) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 2nd line (L2)